key: cord-0784084-bgyz96lf
authors: Kurien, Anila; Ramesh, Jansi
title: Incidence of anti-glomerular basement membrane disease during the COVID-19 pandemic
date: 2021-10-26
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab204
sha: deac5e13e4ef46e99cd181788f0cc4014f59bdf4
doc_id: 784084
cord_uid: bgyz96lf

nan

At the time of kidney biopsy, 39 patients were tested for SARS-CoV-2 infection by viral RNA testing; four patients were positive. Due to the limited availability of the test kits, circulating IgM and/or IgG antibodies to SARS-CoV-2 spike protein was tested only in nine patients and antibodies were detected in seven of them, suggesting recent infection. A negative test for viral RNA does not exclude SARS-CoV-2 infection as the possible triggering factor for the disease since the aberrant adaptive immune response to the virus targeting basement membrane becomes clinically apparent only after some days to weeks after the acute infection. In the study of Prendecki et al, (2) all the eight cases studied were negative for viral RNA but four tested positive for antibodies. Follow up details were available for 20 patients ( Table 2 ) 

Anti-Glomerular Basement Membrane Disease as a Potential Complication of COVID-19: A Case Report and Review of Literature

Anti-glomerular basement membrane disease during the COVID-19 pandemic

A patient with COVID-19 and antiglomerular basement membrane disease

SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

None declared.